Refractory Cancer

Oncology
6
Pipeline Programs
5
Companies
6
Clinical Trials
2 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
4
1
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
1
BIBW 2992Phase 21 trial
Active Trials
NCT01320280Terminated29Est. Nov 2012
IB
Immatics BiotechnologiesGermany - Munich
2 programs
1
1
IMA402Phase 1/21 trial
IMA401Phase 11 trial
Active Trials
NCT05359445Recruiting95Est. Dec 2029
NCT05958121Recruiting145Est. Sep 2027
AT
Actuate TherapeuticsFORT WORTH, TX
1 program
1
9-ING-41Phase 11 trial
Active Trials
NCT04239092TerminatedEst. Jul 2025
NKGEN Biotech
NKGEN BiotechCA - Santa Ana
1 program
1
SNK01Phase 11 trial
Active Trials
NCT03941262Completed27Est. Feb 2023
Genomics
GenomicsUK - Oxford
1 program
1
Treatment based on Molecular ProfilingPhase 11 trial
Active Trials
NCT00530192Completed86Est. Mar 2009

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Boehringer IngelheimBIBW 2992
Immatics BiotechnologiesIMA402
Immatics BiotechnologiesIMA401
Actuate Therapeutics9-ING-41
NKGEN BiotechSNK01
GenomicsTreatment based on Molecular Profiling

Clinical Trials (6)

Total enrollment: 382 patients across 6 trials

NCT01320280Boehringer IngelheimBIBW 2992

BIBW 2992 (Afatinib) for the Treatment of Patients With HER2-positive, Hormone-refractory Prostate Cancer

Start: May 2011Est. completion: Nov 201229 patients
Phase 2Terminated
NCT05958121Immatics BiotechnologiesIMA402

IMA402 T Cell-Engaging Receptor Molecule (TCER®) in Recurrent and/or Refractory Solid Tumors

Start: Aug 2023Est. completion: Sep 2027145 patients
Phase 1/2Recruiting
NCT05359445Immatics BiotechnologiesIMA401

IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor

Start: May 2022Est. completion: Dec 202995 patients
Phase 1Recruiting
NCT04239092Actuate Therapeutics9-ING-41

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Start: Jun 2020Est. completion: Jul 2025
Phase 1Terminated
NCT03941262NKGEN BiotechSNK01

Safety of SNK01 in Subjects With Pathologically Confirmed Metastatic and/or Unresectable Cancer Refractory to Conventional Therapy

Start: Jul 2019Est. completion: Feb 202327 patients
Phase 1Completed
NCT00530192GenomicsTreatment based on Molecular Profiling

Molecular Profiling Protocol (SCRI-CA-001)

Start: Sep 2006Est. completion: Mar 200986 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
1h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
1h ago

Office Administrator

SystImmune
1h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
1h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
1h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
1h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 actively recruiting trials targeting 382 patients
5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)